GSK's Bold $10.6 Billion Bet on Nuvalent Shifts Oncology Strategy

GSK has announced a massive $10.6 billion acquisition of U.S. cancer drug developer Nuvalent, a strategic move under newly appointed CEO Luke Miels. This largest deal within a decade marks a shift from GSK's typical acquisitions, aiming to bolster its oncology sector and withstand future patent expirations.

GSK has made a strategic leap with its $10.6 billion acquisition of Nuvalent, a U.S.-based cancer drug developer, marking its largest deal in over a decade. The all-cash transaction signifies a change in direction under new CEO Luke Miels, steering GSK towards a heightened focus on oncology.

The Nuvalent acquisition, confirmed at $124 per share, represents a 40% premium over the closing price, causing Nuvalent's stock to soar 40% in premarket U.S. trading. GSK, however, experienced a 1.5% drop in its share value in London. Analysts support this strategic move as it aligns with GSK's aim to expand its late-stage pipeline in cancer treatment.

The deal will be primarily funded through debt facilities and cash, expected to close by Q3 2026. As GSK tackles patent challenges and rivals in the sector, acquiring Nuvalent represents a bold investment in pivotal lung cancer treatments projected to significantly boost GSK's revenue prospects in the coming years.